Funder
National High Level Hospital Clinical Research Funding
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference5 articles.
1. Ortín X, Rodríguez-Luaces M, Bosch R, Lejeune M, Font L (2010) Acute liver failure as the first manifestation of very late relapsing of Hodgkin’s disease. Hematol Rep 2(1):e5. https://doi.org/10.4081/hr.2010.e5
2. Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R et al (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8(6):e410–e421. https://doi.org/10.1016/s2352-3026(21)00102-2
3. Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798–2804. https://doi.org/10.1182/blood-2015-06-644336
4. Gupta A, Petrasek J, Sen S, Gopal P, Naina HV (2016) Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment. Clin Lymphoma Myeloma Leuk 16(2):e11–e14. https://doi.org/10.1016/j.clml.2015.11.015
5. Spathas N, Belia M, Giannikos T, Arapaki M, Efstathopoulou M, Tsourouflis G, Gainaru G, Asimakopoulos J, Tsaftaridis P, Angelopoulou MK, Plata E, Konstantopoulos K, Theodoros PV (2019) Successful reversal of severe liver function impairment with brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. J buon 24(6):2483–2489